Cargando…

Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease

(1) Background: TDMQ20 is a specific regulator of copper homeostasis in the brain, able to inhibit cognitive impairment in the early stages of Alzheimer’s disease (AD) in mouse models of AD. To promote the further development of this drug-candidate, preliminary data on the pharmacokinetics of TDMQ20...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Lan, Zeng, Yaoxun, Li, Yongliang, Zhu, Yingshan, He, Yan, Liu, Yan, Robert, Anne, Meunier, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785178/
https://www.ncbi.nlm.nih.gov/pubmed/36559185
http://dx.doi.org/10.3390/pharmaceutics14122691
_version_ 1784857985769537536
author Huang, Lan
Zeng, Yaoxun
Li, Yongliang
Zhu, Yingshan
He, Yan
Liu, Yan
Robert, Anne
Meunier, Bernard
author_facet Huang, Lan
Zeng, Yaoxun
Li, Yongliang
Zhu, Yingshan
He, Yan
Liu, Yan
Robert, Anne
Meunier, Bernard
author_sort Huang, Lan
collection PubMed
description (1) Background: TDMQ20 is a specific regulator of copper homeostasis in the brain, able to inhibit cognitive impairment in the early stages of Alzheimer’s disease (AD) in mouse models of AD. To promote the further development of this drug-candidate, preliminary data on the pharmacokinetics of TDMQ20 in a mammal model have been collected. Since TDMQ20 should be administered orally, its absorption by the gastrointestinal tract was evaluated by comparison of blood concentrations after administration by oral and IV routes, and its ability to reach its target (the brain) was confirmed by comparison between blood and brain concentrations after oral administration. (2) Methods: plasmatic and brain concentrations of the drug after oral or intravenous treatment of rats at pharmacologically relevant doses were determined as a function of time. (3) Results: oral absorption of TDMQ20 was rapid and bioavailability was high (66% and 86% for males and females, respectively). The drug accumulated in the brain for several hours (brain–plasma ratio 3 h after oral administration = 2.6), and was then efficiently cleared. (4) Conclusions: these data confirm that TDMQ20 efficiently crosses the brain–blood barrier and is a relevant drug-candidate to treat AD.
format Online
Article
Text
id pubmed-9785178
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97851782022-12-24 Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease Huang, Lan Zeng, Yaoxun Li, Yongliang Zhu, Yingshan He, Yan Liu, Yan Robert, Anne Meunier, Bernard Pharmaceutics Article (1) Background: TDMQ20 is a specific regulator of copper homeostasis in the brain, able to inhibit cognitive impairment in the early stages of Alzheimer’s disease (AD) in mouse models of AD. To promote the further development of this drug-candidate, preliminary data on the pharmacokinetics of TDMQ20 in a mammal model have been collected. Since TDMQ20 should be administered orally, its absorption by the gastrointestinal tract was evaluated by comparison of blood concentrations after administration by oral and IV routes, and its ability to reach its target (the brain) was confirmed by comparison between blood and brain concentrations after oral administration. (2) Methods: plasmatic and brain concentrations of the drug after oral or intravenous treatment of rats at pharmacologically relevant doses were determined as a function of time. (3) Results: oral absorption of TDMQ20 was rapid and bioavailability was high (66% and 86% for males and females, respectively). The drug accumulated in the brain for several hours (brain–plasma ratio 3 h after oral administration = 2.6), and was then efficiently cleared. (4) Conclusions: these data confirm that TDMQ20 efficiently crosses the brain–blood barrier and is a relevant drug-candidate to treat AD. MDPI 2022-12-01 /pmc/articles/PMC9785178/ /pubmed/36559185 http://dx.doi.org/10.3390/pharmaceutics14122691 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Huang, Lan
Zeng, Yaoxun
Li, Yongliang
Zhu, Yingshan
He, Yan
Liu, Yan
Robert, Anne
Meunier, Bernard
Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease
title Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease
title_full Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease
title_fullStr Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease
title_full_unstemmed Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease
title_short Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease
title_sort distribution in rat blood and brain of tdmq20, a copper chelator designed as a drug-candidate for alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785178/
https://www.ncbi.nlm.nih.gov/pubmed/36559185
http://dx.doi.org/10.3390/pharmaceutics14122691
work_keys_str_mv AT huanglan distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease
AT zengyaoxun distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease
AT liyongliang distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease
AT zhuyingshan distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease
AT heyan distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease
AT liuyan distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease
AT robertanne distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease
AT meunierbernard distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease